Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference, Jan 24
January 09 2018 - 8:30AM
Hemispherx Biopharma, Inc. (NYSE American:HEB),
focused on pharmaceutical research, today announced that Pawel
Kalinski, MD, PhD, Rustum Family Professor for Molecular
Therapeutic and Translational Research at Roswell Park Cancer
Institute in Buffalo, NY, will be presenting data from preclinical
studies and preliminary clinical data on a favorable
immune-modulatory activity of Hemispherx’s Ampligen® on the tumor
microenvironment, which potentially could help convert “cold”
tumors (tumors that are unresponsive to immunotherapy) to tumors
that will respond to immunotherapeutic drugs such as checkpoint
inhibitors.
Checkpoint inhibitors such as anti-PD-1/PD-L1 agents release
effector T cells from immune blockade, thus facilitating an
antitumor attack. Checkpoint inhibitors represent a new
frontier in immuno-oncology and are on a course to achieve more
than $30 billion in sales in the next several years led by Keytruda
(Merck) and Opdivo (Bristol Myers). Currently, the
effectiveness of these drugs is thought to be limited in part by
the ability of the effector T cells to enter the tumor
microenvironment (i.e. cold tumors). These findings were the
result of a series of experiments that included in vitro, in vivo,
and clinical studies.
Dr. Kalinski’s presentation, entitled “Sensitizing Cold Tumors
to Immunotherapy: Selectivity and Specificity of Systemic and Local
Approaches,” will be given at the Immuno-Oncology Frontiers
Conference in Miami, FL on January 24, 2018.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical
company engaged in the clinical development of new drug entities
for treatment of seriously debilitating disorders. Hemispherx’s
flagship products include Alferon N Injection® and the experimental
therapeutic rintatolimod (tradenames Ampligen® or Rintamod®).
Rintatolimod is an experimental RNA nucleic acid being developed
for globally important debilitating diseases and disorders of the
immune system, including Myalgic Encephalomyelitis/Chronic Fatigue
Syndrome (ME/CFS). Hemispherx’s platform technology includes
components for potential treatment of various severely debilitating
and life threatening diseases. Because rintatolimod is experimental
in nature, it is not designated safe and effective by the FDA for
general use and is legally available only through clinical
trials.
Cautionary StatementSome of the statements
included in this press release may be forward-looking statements
that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
set forth in this press release speak only as of the date of this
press release. We do not undertake to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof. This press release and prior releases
are available at www.hemispherx.net. The information found on our
website is not incorporated by reference into this press release
and is included for reference purposes only.
CONTACT
Hemispherx Biopharma Phone Number: 800-778-4042 Email:
IR@hemispherx.net
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Apr 2023 to Apr 2024